Literature DB >> 16971374

Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus.

Michael J Ryan1, Gerald R McLemore.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that predominantly affects women during their reproductive years. Although women with SLE have hypertension, the underlying mechanisms for this have not been examined. Despite the fact that inflammation is associated with altered endothelial and vascular function, the role of altered vascular function in the development of hypertension during SLE is unclear. In the present study, we tested whether a mouse model of SLE (NZBWF1) develops hypertension and examined whether increased blood pressure was associated with impaired endothelial-dependent relaxation. Female NZBWF1 mice were studied at 8, 20, and 36 wk of age. By 36 wk, urinary albumin and antinuclear antibodies were increased in SLE compared with control mice. Mean arterial pressure, measured by radiotelemetry, was significantly increased in SLE mice (124 +/- 4 mmHg, n = 10) compared with control NZW/LacJ mice (111 +/- 3 mmHg, n = 7) at 36 wk. Isolated carotid arteries from NZBWF1 mice, precontracted with U-46619 for assessment of endothelial-dependent relaxation, demonstrated a progressively impaired relaxation to ACh with age, although endothelial nitric oxide synthase mRNA expression was not different. Maximal tension generated by 5-hydroxytryptamine was increased in carotid arteries from NZBWF1 mice compared with controls at 8, 20, and 36 wk of age, suggesting a role for altered vascular function early on in the progression of SLE. Taken together, our data support a role for altered endothelial function as a contributing factor to the development of hypertension during SLE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971374     DOI: 10.1152/ajpregu.00168.2006

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  41 in total

1.  IFN-α Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus.

Authors:  Joy Jones Buie; Ludivine L Renaud; Robin Muise-Helmericks; Jim C Oates
Journal:  J Immunol       Date:  2017-08-04       Impact factor: 5.422

Review 2.  Can estrogens promote hypertension during systemic lupus erythematosus?

Authors:  Marcia Venegas-Pont; Michael J Ryan
Journal:  Steroids       Date:  2010-02-21       Impact factor: 2.668

3.  Autoimmune therapeutic chloroquine lowers blood pressure and improves endothelial function in spontaneously hypertensive rats.

Authors:  Cameron G McCarthy; Camilla F Wenceslau; Styliani Goulopoulou; Safia Ogbi; Takayuki Matsumoto; R Clinton Webb
Journal:  Pharmacol Res       Date:  2016-09-14       Impact factor: 7.658

4.  Preventing autoimmunity protects against the development of hypertension and renal injury.

Authors:  Keisa W Mathis; Kedra Wallace; Elizabeth R Flynn; Christine Maric-Bilkan; Babbette LaMarca; Michael J Ryan
Journal:  Hypertension       Date:  2014-07-14       Impact factor: 10.190

5.  Sex and basic science. A Title IX position.

Authors:  Kathryn Sandberg; Joseph G Verbalis; Gina L C Yosten; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-06-18       Impact factor: 3.619

6.  Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.

Authors:  Nicole L Regna; Cristen B Chafin; Sarah E Hammond; Abdul G Puthiyaveetil; David L Caudell; Christopher M Reilly
Journal:  Clin Immunol       Date:  2014-01-15       Impact factor: 3.969

Review 7.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

8.  Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.

Authors:  Erin B Taylor; Michelle T Barati; David W Powell; Hannah R Turbeville; Michael J Ryan
Journal:  Hypertension       Date:  2018-01-29       Impact factor: 10.190

9.  The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

Authors:  Wenpu Zhao; Seth G Thacker; Jeffrey B Hodgin; Hongyu Zhang; Jeffrey H Wang; James L Park; Ann Randolph; Emily C Somers; Subramaniam Pennathur; Matthias Kretzler; Frank C Brosius; Mariana J Kaplan
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

Review 10.  The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension.

Authors:  Steven D Crowley
Journal:  Antioxid Redox Signal       Date:  2013-04-19       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.